National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 19/10/2017
Rapid review completed 23/11/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 29/11/2017
Pre-submission consultation with Applicant 06/02/2018
Submission received from Applicant 11/07/2018
Preliminary review sent to Applicant 20/08/2018
NCPE assessment recommenced 18/09/2018
Factual accuracy sent to Applicant 04/10/2018
Factual accuracy returned to NCPE 12/10/2018
NCPE Assessment Complete
18/10/2018
NCPE Assessment Outcome
Following assessment of the applicant’s submission, the NCPE recommends that dinutuximab beta (Qarziba®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.

Summary